statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel...

Opthea to Participate in the 23  Annual Needham Virtual Healthcare Conference

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee ChairMELBOURNE, Australia and PRINCETON, N.J., April 03...

Opthea Appoints Sujal Shah to the Board of Directors

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to...

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Opthea Limited (NASDAQ:OPT  Get Free Report) was the target of a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 124,100 shares...

Short Interest in Opthea Limited (NASDAQ:OPT) Decreases By 21.1%

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Opthea (NASDAQ:OPT  Get Free Report) and Amgen (NASDAQ:AMGN  Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on...

Financial Review: Opthea (NASDAQ:OPT) vs. Amgen (NASDAQ:AMGN)

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr...

Opthea Reports Half-Year Financial Results and Business Updates

Surrozen (NASDAQ:SRZN  Get Free Report) and Opthea (NASDAQ:OPT  Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

Analyzing Opthea (NASDAQ:OPT) and Surrozen (NASDAQ:SRZN)

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, Opthea ), a...

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

COAST trial is evaluating the superiority of sozinibercept combined with EYLEA (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024...

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.

Volume	2,381.00
52-Wk High	$4.42
52-Wk Low	$1.60

OPT Opthea Limited - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals